{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Birmingham DJ"],"funding":["NIDDK NIH HHS","NCRR NIH HHS"],"pagination":["47-53"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4702227"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["<h4>Background and objectives</h4>Autoantibodies to complement C1q (anti-C1q) are associated with the diagnosis of lupus nephritis. In this study, we compare anti-C1q IgG with another complement autoantibody, anti-C3b IgG, as a biomarker of lupus nephritis and lupus nephritis flare.<h4>Design, setting, participants, & measurements</h4>Our investigation involved the Ohio SLE Study, a prospective observational cohort of patients with recurrently active lupus who were followed bimonthly. Serum anti-C1q and anti-C3b IgG levels were assessed cross-sectionally by ELISA in 40 normal controls and 114 patients in the Ohio SLE Study (41 nonrenal and 73 lupus nephritis) at study entry, and longitudinally in a subset of patients in the Ohio SLE Study with anti-C1q-positive lupus nephritis in samples c"],"journal":["Clinical journal of the American Society of Nephrology : CJASN"],"pubmed_title":["Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare."],"pmcid":["PMC4702227"],"funding_grant_id":["P01 DK55546","UL1 RR025755","P01 DK055546"],"pubmed_authors":["Gullo TR","Ndukwe EG","Rovin BH","Birmingham DJ","Dials S","Nagaraja HN","Hebert LA","Bitter JE","Conroy S"],"additional_accession":[]},"is_claimable":false,"name":"Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare.","description":"<h4>Background and objectives</h4>Autoantibodies to complement C1q (anti-C1q) are associated with the diagnosis of lupus nephritis. In this study, we compare anti-C1q IgG with another complement autoantibody, anti-C3b IgG, as a biomarker of lupus nephritis and lupus nephritis flare.<h4>Design, setting, participants, & measurements</h4>Our investigation involved the Ohio SLE Study, a prospective observational cohort of patients with recurrently active lupus who were followed bimonthly. Serum anti-C1q and anti-C3b IgG levels were assessed cross-sectionally by ELISA in 40 normal controls and 114 patients in the Ohio SLE Study (41 nonrenal and 73 lupus nephritis) at study entry, and longitudinally in a subset of patients in the Ohio SLE Study with anti-C1q-positive lupus nephritis in samples c","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jan","modification":"2025-04-22T19:50:43.205Z","creation":"2019-03-27T02:06:20Z"},"accession":"S-EPMC4702227","cross_references":{"pubmed":["26700439"],"doi":["10.2215/cjn.03990415","10.2215/CJN.03990415"]}}